Compositions comprising fusion variants of FGF19 polypeptides
US9670260B2 · kind B2 · utility
33Cited by
55References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2015 |
| Grant date | Jun 6, 2017 |
| Priority date | — |
| Expiry date | Dec 29, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/66
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.